EUVIMEDEUVIMED entdecken
Fallbericht

Eculizumab as rescue therapy for antibody-mediated rejection in a high-risk lung transplant recipient: A case report

Adrian Puertas Sanjuan, Judith Sacanell-Lacasa, Maria Rosa Gómez Domingo, Alba Pau-Parra, Jordi Riera Del Brio, Cristina Berastegui, Irina B Torres, Joel Rosado Rodriguez, Pilar Lalueza Broto, Laura Doménech-Moral

American Journal of Health-System Pharmacy · 09.03.2026 · 83 (6) · 266-271

DOI: 10.1093/ajhp/zxaf298 ↗

Kurz gefasst

Fallbericht in der Zeitschrift American Journal of Health-System Pharmacy, online erschienen am 30.10.2025. Verfasst von Adrian Puertas Sanjuan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy, Vall d'Hebron University Hospital, Barcelona, Spain. Hauptthemen laut MEDLINE: Lung Transplantation, Antibodies, Monoclonal, Humanized, Graft Rejection. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To describe the management of refractory antibody-mediated rejection (AMR) in a highly sensitized lung transplant recipient, emphasizing the use of eculizumab as rescue therapy, and to highlight the importance of continuous monitoring in posttransplant patients and the role of multidisciplinary teams in addressing complex cases of graft rejection. Summary This case report describes a 58-year-old woman with high immunologic risk who underwent bilateral lung transplantation. The patient did not receive pretransplant desensitization. In the early posttransplant period, she developed possible AMR with severe respiratory deterioration and required venovenous extracorporeal membrane oxygenation (ECMO). Initial treatment included corticosteroids, plasmapheresis, intravenous immune globulins, and thymoglobulin. However, donor-specific antibodies levels increased, and the patient’s respiratory condition deteriorated further. Eculizumab was administered as second-line therapy, leading to both clinical and immunological improvement. The patient survived and was eventually discharged from the intensive care unit.

Conclusion

Eculizumab may represent a viable rescue option in cases of refractory AMR after lung transplantation, including in patients requiring ECMO support. This case highlights the importance of tailored therapeutic strategies and multidisciplinary evaluation in managing high-risk transplant recipients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung TransplantationAntibodies, Monoclonal, HumanizedGraft RejectionHumansFemaleMiddle AgedExtracorporeal Membrane OxygenationImmunosuppressive Agents

Stichwörter der Autor:innen

antibody-mediated rejectiondonor-specific antibodieseculizumabhighly sensitized recipientlung transplantation

Substanzen

eculizumabAntibodies, Monoclonal, HumanizedImmunosuppressive Agents

Autor:innen und Institutionen

  • Pharmacy, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Critical Care Unit, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Lung Transplant Unit, Department of Respiratory Medicine, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Department of Nephrology, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Department of Thoracic Surgery, Vall d'Hebron University Hospital, Barcelona, Spain.

Zitieren

APA

Puertas Sanjuan, A., Sacanell-Lacasa, J., Gómez Domingo, M. R., Pau-Parra, A., Riera Del Brio, J., Berastegui, C., Torres, I. B., Rosado Rodriguez, J., Lalueza Broto, P., & Doménech-Moral, L. (2026). Eculizumab as rescue therapy for antibody-mediated rejection in a high-risk lung transplant recipient: A case report. American Journal of Health-System Pharmacy, 83(6), 266-271. https://doi.org/10.1093/ajhp/zxaf298

Vancouver

Puertas Sanjuan A, Sacanell-Lacasa J, Gómez Domingo MR, Pau-Parra A, Riera Del Brio J, Berastegui C, et al. Eculizumab as rescue therapy for antibody-mediated rejection in a high-risk lung transplant recipient: A case report. American Journal of Health-System Pharmacy. 2026;83(6):266-271. doi:10.1093/ajhp/zxaf298

BibTeX
@article{PuertasSanjuan2026,
  author = {Puertas Sanjuan, Adrian and Sacanell-Lacasa, Judith and Gómez Domingo, Maria Rosa and Pau-Parra, Alba and Riera Del Brio, Jordi and Berastegui, Cristina and Torres, Irina B and Rosado Rodriguez, Joel and Lalueza Broto, Pilar and Doménech-Moral, Laura},
  title = {Eculizumab as rescue therapy for antibody-mediated rejection in a high-risk lung transplant recipient: A case report},
  journal = {American Journal of Health-System Pharmacy},
  year = {2026},
  volume = {83},
  number = {6},
  pages = {266--271},
  doi = {10.1093/ajhp/zxaf298}
}
Kostenlos starten →